AUS
NZ
UK
CA
USA
IND
Highlights:
-
IQ-AI Ltd is nearing completion of its Phase I clinical trial for IB003, a gallium maltolate therapy targeting children's brain cancer, with only two patients remaining for enrollment.
-
The company is preparing for a critical meeting with the U.S. Food and Drug Administration (FDA) to advance the treatment's development and has established three active sites for its Expanded Access Program (EAP).
-
IQ-AI has received a Rare Pediatric Disease Designation from the FDA, potentially expediting regulatory approval for the treatment.
IQ-AI Ltd (OTC:IQAIF) has announced significant progress in the Phase I clinical trial of its IB003 cancer treatment, specifically designed for pediatric brain cancer. With only two patients left to enroll, the company is poised to transition into Phase II of the trial, which will involve a larger cohort to further evaluate the treatment's effectiveness. Initial data has indicated that IB003 is safe and shows promising signs of success.
In a recent communication to shareholders, Michael Schmainda, CEO of the company's Imaging Biometrics division, provided updates on the trial and indicated that preparations are underway for an essential meeting with the FDA. This meeting is expected to facilitate the drug's advancement through regulatory pathways.
The progress of the Expanded Access Program (EAP), which allows non-trial patients to access IB003, has experienced delays primarily due to hospital approval processes. However, three sites located in New York, North Carolina, and California are now operational, with two patients already receiving the treatment.
IQ-AI retains full rights to the data collected from the Phase I trial and remains dedicated to advancing the drug through subsequent phases of development. Preliminary findings suggest no toxic side effects, reinforcing the treatment's potential.
Additionally, IQ-AI has achieved a Rare Pediatric Disease Designation (RPDD) from the FDA, which could provide a significant regulatory advantage. Legislative efforts are currently underway to extend the RPDD program beyond its scheduled expiration in 2026.
Beyond the drug trials, IQ-AI has launched a promotional video for its IB Nimble device, designed to support healthcare professionals in managing complex diseases. The company is also advancing its AI-driven technology, IB Zero G, aimed at enhancing medical imaging for vulnerable patient groups. With Phase I trial results and EAP data anticipated in early 2025, IQ-AI is exploring various funding options to bolster its growth strategy.
